Association between serum magnesium levels and cognitive function in patients undergoing hemodialysis
Clinical and Experimental Nephrology · 2024
DOI: 10.1007/s10157-024-02528-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Kazuhiko Kato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Renal Dialysis, Magnesium, Fibroblast Growth Factor-23, Cognition. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: JSPS KAKENHI, The Kidney Foundation, Japan, Jikei University School of Medicine.
Abstract (Originalsprache)
BACKGROUND: The relationship between chronic kidney disease-mineral and bone disorder (CKD-MBD) and cognitive function remains largely unknown. This cross-sectional study aimed to explore the association between CKD-MBD and cognitive function in patients on hemodialysis. METHODS: Hemodialysis patients aged ≥ 65 years without diagnosed dementia were included. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). CKD-MBD markers, serum magnesium, intact parathyroid hormone (PTH), 25-hydroxyvitamin D (25-OHD), fibroblast growth factor (FGF)-23, and soluble α-klotho were measured. RESULTS: Overall, 390 patients with a median age of 74 (interquartile range, 70-80) years, mean serum magnesium level of 2.4 ± 0.3 mg/dL, and median MoCA and MMSE scores of 25 (22-26) and 28 (26-29), respectively, were analyzed. MoCA and MMSE scores were significantly higher (preserved cognitive function) in the high-magnesium group than in the low-magnesium group according to the unadjusted linear regression analysis (β coefficient [95% confidence interval (CI)] 1.05 [0.19, 1.92], P = 0.017 for MoCA; 1.2 [0.46, 1.94], P = 0.002 for MMSE) and adjusted multivariate analysis with risk factors for dementia (β coefficient [95% CI] 1.12 [0.22, 2.02], P = 0.015 for MoCA; 0.92 [0.19, 1.65], P = 0.014 for MMSE). CONCLUSIONS: Higher serum magnesium levels might be associated with preserved cognitive function in hemodialysis patients. Conversely, significant associations were not observed between cognitive function and intact PTH, 25-OHD, FGF-23, or soluble α-klotho levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
- Division of Molecular Epidemiology, The Jikei University School of Medicine, Tokyo, Japan.
- Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. a-nakashima@jikei.ac.jp.
- Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.
- Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Förderung
- JSPS KAKENHI
- The Kidney Foundation, Japan
- Jikei University School of Medicine
Zitieren
APA
Kato, K., Nakashima, A., Shinagawa, S., Kobayashi, A., Ohkido, I., Urashima, M., & Yokoo, T. (2024). Association between serum magnesium levels and cognitive function in patients undergoing hemodialysis. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02528-0
Vancouver
Kato K, Nakashima A, Shinagawa S, Kobayashi A, Ohkido I, Urashima M, et al. Association between serum magnesium levels and cognitive function in patients undergoing hemodialysis. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02528-0
BibTeX
@article{Kato2024,
author = {Kato, Kazuhiko and Nakashima, Akio and Shinagawa, Shunichiro and Kobayashi, Arisa and Ohkido, Ichiro and Urashima, Mitsuyoshi and Yokoo, Takashi},
title = {Association between serum magnesium levels and cognitive function in patients undergoing hemodialysis},
journal = {Clinical and Experimental Nephrology},
year = {2024},
doi = {10.1007/s10157-024-02528-0}
}
EUVIMED